Compare MEG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | GHRS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | Ireland |
| Employees | 3500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 808.2M |
| IPO Year | 2020 | 2021 |
| Metric | MEG | GHRS |
|---|---|---|
| Price | $22.36 | $14.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $35.25 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 302.7K | 195.9K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $830,538,000.00 | N/A |
| Revenue This Year | $5.46 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.26 | N/A |
| 52 Week Low | $10.51 | $7.98 |
| 52 Week High | $32.00 | $19.51 |
| Indicator | MEG | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 52.59 |
| Support Level | $21.11 | $12.27 |
| Resistance Level | $23.78 | $16.29 |
| Average True Range (ATR) | 1.08 | 0.88 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 28.41 | 69.30 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.